We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia.
- Authors
Yaqiong Tang; Qian Wu; Xiaojin Wu; Huiying Qiu; Aining Sun; Changgeng Ruan; Depei Wu; Yue Han
- Abstract
Background and Objective: Recombinant-activated factor VII (rVIIa) is a vitamin K-dependent glycoprotein that is an analog of the naturally occurring protease. It has an off-label use to control life-threatening bleeding that is refractory to other measures and was shown to decrease transfusion requirements. Gastrointestinal (GI) bleeding is a severe complication following hematopoietic stem cell transplantation (HSCT) in patients with thrombocytopenia, while hemostatic measures based on antifibrinolytic or transfusion therapy may not always be successful. The present study investigated the treatment with rFVIIa in severe GI bleeding among thrombocytopenia patients undergoing HSCT. Methods: rFVIIa was given as a single dose of 60µg/kg in patients with GI bleeding following hematopoietic stem cell transplantation (HSCT). Results: Among all patients enrolled, 12 (75%) of 16 patients obtained a response, of which 5 achieved a complete response and 7 achieved a partial response. The 4 remiaing patients (25%) had no response. Nine patients (56.3%) died in a follow-up of 90 days. No thromboembolic events wereassociated with the drug administration occurred. Conclusions: Our study showed that rFVIIa may represent an additional therapeutic option in such cases.
- Subjects
GASTROINTESTINAL hemorrhage; HEMATOPOIETIC stem cell transplantation; THROMBOCYTOPENIA treatment; BLOOD transfusion; DRUG administration
- Publication
Pakistan Journal of Medical Sciences, 2015, Vol 31, Issue 6, p1389
- ISSN
1682-024X
- Publication type
Article
- DOI
10.12669/pjms.316.8357